Paper39014279
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review.
Mansilla-Polo M and 1 other. Dermatol Ther (Heidelb), 2024. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review. Papers, record 39014279. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39014279
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References126
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30581616 | Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. | J Adv Res | 2019 | https://conductscience.org/library/papers/30581616 | PubMed |
| 2 | 33419176 | Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/33419176 | PubMed |
| 3 | 29908671 | New-generation JAK inhibitors: how selective can they be? | Lancet | 2018 | https://conductscience.org/library/papers/29908671 | PubMed |
| 4 | 37331618 | Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders. | Actas Dermosifiliogr | 2023 | https://conductscience.org/library/papers/37331618 | PubMed |
| 5 | 37596779 | JAK inhibitors and black box warnings: what is the future for JAK inhibitors? | Expert Rev Clin Immunol | 2023 | https://conductscience.org/library/papers/37596779 | PubMed |
| 6 | 22532633 | Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. | Ann Rheum Dis | 2013 | https://conductscience.org/library/papers/22532633 | PubMed |
| 7 | 23240738 | Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. | Aliment Pharmacol Ther | 2013 | https://conductscience.org/library/papers/23240738 | PubMed |
| 8 | 23462785 | Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. | JAMA | 2013 | https://conductscience.org/library/papers/23462785 | PubMed |
| 9 | 24462626 | Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. | Clin Gastroenterol Hepatol | 2014 | https://conductscience.org/library/papers/24462626 | PubMed |
| 10 | 24414744 | Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. | Rheumatol Int | 2014 | https://conductscience.org/library/papers/24414744 | PubMed |
| 11 | 25557144 | Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden. | Int J Rheum Dis | 2015 | https://conductscience.org/library/papers/25557144 | PubMed |
| 12 | 26472414 | The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies. | J Rheumatol | 2015 | https://conductscience.org/library/papers/26472414 | PubMed |
| 13 | 25970800 | Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). | JAMA Dermatol | 2015 | https://conductscience.org/library/papers/25970800 | PubMed |
| 14 | 28160418 | Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. | Int J Rheum Dis | 2017 | https://conductscience.org/library/papers/28160418 | PubMed |
| 15 | 28336735 | Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. | BMJ Open | 2017 | https://conductscience.org/library/papers/28336735 | PubMed |
| 16 | 29054603 | Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). | J Invest Dermatol | 2018 | https://conductscience.org/library/papers/29054603 | PubMed |
| 17 | 28717941 | The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials. | Clin Rev Allergy Immunol | 2018 | https://conductscience.org/library/papers/28717941 | PubMed |
| 18 | 29655835 | Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. | Gastroenterology | 2018 | https://conductscience.org/library/papers/29655835 | PubMed |
| 19 | 30763469 | Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study. | J Clin Pharm Ther | 2019 | https://conductscience.org/library/papers/30763469 | PubMed |
| 20 | 31799498 | Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. | BMC Rheumatol | 2019 | https://conductscience.org/library/papers/31799498 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42930036 | Antibody-Related Mechanisms in Ocular Diseases: Autoimmunity, Malignancy, and Therapeutic Targeting. | Antibodies (Basel) | 2026 | https://conductscience.org/library/papers/42930036 | PubMed |
| 42663861 | Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/42663861 | PubMed |
| 42566613 | Rare primary bone tuberculosis associated with ruxolitinib therapy: A case report and literature review. | Medicine (Baltimore) | 2026 | https://conductscience.org/library/papers/42566613 | PubMed |
| 42459641 | Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center retrospective study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42459641 | PubMed |
| 42397402 | [Vaccination of immunocompromised individuals: Expert opinion - update 2026]. | Wien Klin Wochenschr | 2026 | https://conductscience.org/library/papers/42397402 | PubMed |
| 42312036 | Global, regional, and national burden of bone and joint infections, 1990-2021: a comprehensive analysis of trends, pathogens, and antimicrobial resistance. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42312036 | PubMed |
| 42176150 | PCR-confirmed severe geographic HSV-1 keratitis associated with systemic JAK inhibitor therapy. | J Ophthalmic Inflamm Infect | 2026 | https://conductscience.org/library/papers/42176150 | PubMed |
| 42169865 | Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar. | Clin Med Insights Arthritis Musculoskelet Disord | 2026 | https://conductscience.org/library/papers/42169865 | PubMed |
| 42133200 | Dermatologic Toxicities Induced by JAK Inhibitors. | Am J Clin Dermatol | 2026 | https://conductscience.org/library/papers/42133200 | PubMed |
| 42047749 | [Biologics and infections: understand and recognize]. | Dermatologie (Heidelb) | 2026 | https://conductscience.org/library/papers/42047749 | PubMed |
| 41978829 | Post-translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41978829 | PubMed |
| 41526852 | From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report. | BMC Ophthalmol | 2026 | https://conductscience.org/library/papers/41526852 | PubMed |
| 41418047 | Trends in mortality, pathogen distribution, and antimicrobial resistance of peritoneal and intra-abdominal infections from 1990 to 2021: a cross-sectional analysis of the MICROBE database. | Int J Surg | 2025 | https://conductscience.org/library/papers/41418047 | PubMed |
| 41393140 | Therapeutic potential of peptidomimetics of suppressors of cytokine signaling (SOCS) proteins in rheumatic disorders. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41393140 | PubMed |
| 41373641 | From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41373641 | PubMed |
| 40949126 | Ruxolitinib alleviates DSS-induced acute ulcerative colitis by inhibiting STAT1 phosphorylation and reducing MDSC infiltration. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40949126 | PubMed |
| 40949078 | Janus Kinase Inhibitors As Emerging Therapy in the Treatment of Psoriatic Arthritis: A Narrative Review of Efficacy, Safety, and Future Perspective. | Cureus | 2025 | https://conductscience.org/library/papers/40949078 | PubMed |
| 40860887 | Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40860887 | PubMed |
| 40725743 | Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment. | J Clin Med | 2025 | https://conductscience.org/library/papers/40725743 | PubMed |
| 40717929 | Successful Treatment of Recalcitrant Eosinophilic Pustular Folliculitis with Dupilumab. | Sultan Qaboos Univ Med J | 2025 | https://conductscience.org/library/papers/40717929 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IL1A | 3552 | PubTator's text mining | https://conductscience.org/library/genes/3552 | NCBI Gene |
| IL23A | 51561 | PubTator's text mining | https://conductscience.org/library/genes/51561 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39014279
GET https://conductscience.org/api/papers/v1/39014279/references?page=2